MEDOVEX
Medovex Pty Ltd is an Australian privately held medical device company that develops and manufactures the DenerveX System, a minimally invasive rotational ablation device for long-lasting relief of chronic facet joint syndrome pain, sold to spine physicians and chronic back-pain patients via distribution partners with first commercial approval received in the UK in January 2025.
- Company typePrivate
- Founded2013
- HeadquartersAtlanta, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What MEDOVEX does
Medovex Pty Ltd is a privately held medical device company that develops and manufactures the DenerveX System, a minimally invasive device designed to deliver long-lasting pain relief for patients with chronic facet joint syndrome (osteoarthritis of the spine). The company is domiciled in Australia, with manufacturing operations in Kent Town, South Australia, and a registered office in Smithfield, NSW, and it was previously listed on NASDAQ under the ticker MDVXU before going private. Its core technology, branded as Rotacapsulation (Rotational Ablation Denervation), uses a handheld device synchronized with a proprietary power generator to apply controlled rotation and heat to facet joints through a 1cm procedural portal under fluoroscopic guidance, with each treatment location taking no more than 30 seconds. The procedure requires only a 10-15 millimeter incision and offers an expected one-to-two week recovery, positioning the product as an alternative to standard radio frequency (RF) ablation, which the company describes as providing only temporary relief.
The company sells the DenerveX System through two channels: a network of distribution partners that carry established spine product portfolios and direct contacts with healthcare professionals interested in performing the procedure. Medovex operates with 1-10 employees and targets two primary segments: spine physicians seeking durable pain-relief solutions for facet joint syndrome patients and chronic back-pain patients who have not responded to conservative treatments such as pain medication, physical therapy, or spinal injections. As of January 25, 2025, the DenerveX System received regulatory approval for use in the UK, which represents the company's first documented commercial market. Management is led by CEO and President Robert Greif, Chairman Larry Papasan, and CFO Charles Farrahar, and the company has a track record of inorganic portfolio expansion through the acquisitions of Streamline (2015) and Regenerative Medicine Solutions (2018), though it currently derives its strategic focus from the DenerveX product line. Pricing is not publicly disclosed, and no recurring software or service revenue stream has been disclosed.
MEDOVEX firmographics
Firmographics- Name
- MEDOVEX
- Legal name
- Medovex Pty Ltd
- Website
- https://medovex.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Medovex Pty Ltd is an Australian privately held medical device company that develops and manufactures the DenerveX System, a minimally invasive rotational ablation device for long-lasting relief of chronic facet joint syndrome pain, sold to spine physicians and chronic back-pain patients via distribution partners with first commercial approval received in the UK in January 2025.
- Ownership category
- akta.pro rank
MEDOVEX industry classification
Industry- Product category
- Minimally Invasive Spinal Pain Management Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Condition-specific Digital Therapeutics (DTx) (HLACANAA)
- akta.pro secondary industry
- DTx/SaMD Regulatory, Quality & Compliance Software (QMS/ISO/FDA) (HLACANAN)
Keywords
Where MEDOVEX is headquartered
LocationHeadquarters
- HQ city
- Atlanta
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
MEDOVEX business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Technology or R&D, Supply Chain, Marketing or Sales, Personnel
Revenue model
- Medical Device Sales: Medovex generates revenue through the sale of the DenerveX system, which includes the handheld device and power generator. The company sells directly to healthcare providers and through distribution partners.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
MEDOVEX product offering
Product offeringCore offering
MEDOVEX develops, manufactures, and commercializes the DenerveX System, a minimally invasive medical device that uses proprietary Rotational Ablation Denervation (Rotacapsulation) technology to provide long-lasting pain relief for patients suffering from chronic back pain caused by facet joint disorders (Facet Joint Syndrome). The system consists of a handheld device synchronized with a power generator and is sold to healthcare providers either directly or through distribution partners, with the product currently available in the UK following regulatory approval in January 2025.
Product overview
Medovex offers a single unified medical device product: the DenerveX System. The DenerveX System consists of a small hand-held device synchronized with a specifically designed power generator. The system is designed for rotational ablation denervation (Rotacapsulation) of facet joints to provide enduring relief from facet joint pain. The procedure is minimally invasive, requiring a small incision of 10-15 millimeters, with recovery time of one to two weeks. The DenerveX System has been used to treat over 1,500 patients.
Differentiator
Problem solved
Functional benefit
Brands
- DenerveX®: The DenerveX® system is an innovative, minimally invasive therapy designed to provide long-lasting pain relief from chronic back pain caused by facet joint disorders. It uses rotational ablation denervation technology.
Products and services
- DenerveX System The DenerveX System is an innovative, minimally invasive medical device designed to provide long-lasting pain relief from chronic back pain caused by facet joint disorders. It uses proprietary rotational ablation denervation (Rotacapsulation) technology, combining high heat and light tissue scraping action on the back of the facet joint to disrupt pain signals and receptors. The system consists of a handheld device synchronized with a specifically designed power generator, and is intended for use by spine physicians and pain management specialists to treat patients with Facet Joint Syndrome (osteoarthritis) who have not responded to conservative treatments such as pain relievers, physical therapy, and spinal injections.
Quantifiable outcome
- Over 1,500 patients treated successfully with long-lasting pain relief
- +2 more outcomes
Companies that use MEDOVEX
Customer profileSegments2 records
Ideal customer profiles2 records
MEDOVEX technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
MEDOVEX partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Unnamed Distribution PartnerscoreMedovex has established a network of distribution partners who carry the spine product portfolio including the DenerveX system. The company is actively seeking additional distribution partners who have established reputations in the spine product market.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
MEDOVEX competitors and assessment
Company assessmentDirect peers
- Vertos Medical: Vertos Medical offers the mild procedure, a minimally invasive treatment for lumbar spinal stenosis. It is a comparable minimally invasive spine therapy targeting the same interventional pain and spine surgeon customer base that MEDOVEX addresses with DenerveX.
- SI-BONE: SI-BONE markets the iFuse Implant System for sacroiliac joint dysfunction, a minimally invasive spine/joint pain therapy. SI-BONE competes for the same chronic joint pain patient pool (facet joint vs. SI joint) and the same surgeon specialty community.
- PainTEQ: PainTEQ develops minimally invasive procedures for joint pain, including the LinQ procedure for sacroiliac joint dysfunction. It targets the same interventional pain management physician customer and competes for the same chronic joint pain patient population.
- Relievant Medsystems: Relievant Medsystems offers the Intracept procedure, a minimally invasive basivertebral nerve ablation treatment for chronic vertebrogenic low back pain — the closest analog to DenerveX in terms of minimally invasive nerve ablation for chronic spine pain. Same target specialty (interventional pain/spine), same minimally invasive ethos, similar reimbursement pathway.
Emerging players
- Spinal Simplicity: Spinal Simplicity offers the Minuteman and Liberty spine stabilization devices for minimally invasive treatment of spinal conditions. It is an emerging player in the same minimally invasive spine therapy category targeting interventional pain specialists.
- Nevro: Nevro markets the HFX spinal cord stimulation platform for chronic pain, including back and leg pain. It represents an emerging alternative modality (neuromodulation) that addresses the same chronic pain patient population and competes for interventional pain physician adoption.
Broad incumbents
- Stryker: Stryker's Spine division offers a broad portfolio of spine implants, navigation, and pain therapies. As a diversified spine incumbent, it competes broadly with MEDOVEX in hospital purchasing decisions for interventional pain therapies.
- Abbott: Abbott's spinal cord stimulation and neuromodulation portfolio (acquired via St. Jude) addresses chronic pain including back pain. As a broad incumbent with established hospital relationships and reimbursement infrastructure, it represents the dominant competitive alternative for spine pain procedures.
- Medtronic: Medtronic operates a major Spine division offering fusion, biologics, and pain therapies that compete with DenerveX's addressable market. As the largest spine medtech incumbent, it shapes surgeon training, reimbursement, and hospital purchasing decisions relevant to MEDOVEX's commercial pathway.
- Boston Scientific: Boston Scientific has a substantial pain management portfolio including radiofrequency ablation systems that compete directly with DenerveX as the incumbent standard of care. As a diversified medtech incumbent, it sets the competitive benchmark in facet joint pain treatment that MEDOVEX positions against.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
MEDOVEX social profiles
Digital presenceMEDOVEX financial estimates
Financial estimateRevenue estimate
Valuation estimate
MEDOVEX leadership team
Management profileNumber of profiles
Profiles3 records
MEDOVEX funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MEDOVEX M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MEDOVEX
What does MEDOVEX do?
MEDOVEX develops, manufactures, and commercializes the DenerveX System, a minimally invasive medical device that uses proprietary Rotational Ablation Denervation (Rotacapsulation) technology to provide long-lasting pain relief for patients suffering from chronic back pain caused by facet joint disorders (Facet Joint Syndrome). The system consists of a handheld device synchronized with a power generator and is sold to healthcare providers either directly or through distribution partners, with the product currently available in the UK following regulatory approval in January 2025.
Is MEDOVEX a public or private company?
MEDOVEX is a private company. It is classified as unknown and is currently operating.
When was MEDOVEX founded?
MEDOVEX was founded in 2013. It employs 1 to 10 people.
Where is MEDOVEX based?
MEDOVEX is headquartered in Atlanta, United States, in the North America region.
How does MEDOVEX make money?
One revenue line is on record: medical Device Sales.
Who are MEDOVEX's main competitors?
Direct peers on record are Vertos Medical, SI-BONE, PainTEQ and Relievant Medsystems. Emerging players are Spinal Simplicity and Nevro. Broad incumbents are Stryker, Abbott, Medtronic and Boston Scientific.
Does MEDOVEX have an API?
No public API is recorded for MEDOVEX.
What industry is MEDOVEX in?
MEDOVEX's product category is Minimally Invasive Spinal Pain Management Devices. Its primary akta.pro industry code is HLACANAA, Condition-specific Digital Therapeutics (DTx), with a secondary code of HLACANAN, DTx/SaMD Regulatory, Quality & Compliance Software (QMS/ISO/FDA). Its NAICS code is 339112 and its SIC code is 3841.